Pluvicto

​Pluvicto

What is Pluvico?
Pluvicto(r) is a very high-tech and targeted medications that is used to treat men with advanced prostate cancer. Pluvicto has been shown to help men with advanced prostate cancer feel better and live longer. Our medical practice is among the first in the regional to start treating with Pluvicto and we have quite a bit of experience with taking care of men who have advanced prostate cancer.

To schedule an initial consultation to see if you are a good candidate for Pluvicto, you or your cancer doctor can call our team at 504-503-5139 and press option 2 to schedule.

Which men benefit from Pluvicto?
Pluvicto has shown positive effects on men with metastatic castrate-resistant prostate cancer. These are men whose prostate cancer has spread from the prostate usually into lymph nodes and the bone, and sometimes into other organs. Castrate-resistant refers to men who are no longer responding well to anti-androgen medications including Lupron, Eligard, abiraterone, or enzalutamide.

What do you need to know about Pluvicto therapy?
Pluvicto is most often given once every six weeks for six cycles in total. Our physicians take less than five minutes to administer the drug, and our patients are often headed back home within one hour of arriving. This schedule is very patient-friendly – this schedule makes it easier to treat patients from Alabama, Louisiana, Mississippi, and beyond, as the disruption on your life and visits to our Center are fairly limited. We are happy to work closely with your local doctors and treatment team. Patients will continue with their treatment team after Pluvicto is complete.

How does it work?
Pluvicto contains both a radiotracer known as anti-PSMA, which selective binds to prostate cancer cells, and also a payload of a radioactive particle known as Lutetium-177. This allows Pluvicto to be specific and selective, focusing on prostate cancer cells while causing much less damage to non-target healthy tissues.

It is important to understand that we will ask you to do your part to help protection the general population from getting radiation exposure from this drug.

Case study
This is a man in his early 80s who was referred to us for advanced prostate cancer with disease in the bones and liver and a PSA of 24.

Before: Figure 1 shows multiple areas of PSMA-uptake (the dark areas) which shows prostate cancer in the bones and liver nodes. This was performed about one month before starting Pluvicto.

After: Figure 2 shows that all the areas of PSMA-uptake have resolved about two months after his sixth and final dose of Pluvicto. His PSA has decreased to non-detectable (<0.04). Almost two years later, his PSA remains low at about 1.0.

Given his decline in early PSA along with his post-treatment imaging showing an excellent response of all disease and no new disease, treating him with Pluvicto should substantially prolong survival.

Please note that this one specific patient example and that results vary; your result may be different.